Preventing Adverse Events in High-Risk Cardiometabolic Patients with Peripheral Artery Disease
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
Furthermore, peripheral revascularization has become increasingly common in PAD patients, however, patients who undergo this procedure are still at an increased risk for future adverse events, particularly for acute limb ischemia. Given these heightened risks in PAD patients with cardiometabolic disease or risk, traditional antiplatelet strategies may not be adequate. Several clinical trials have been recently concluded or ongoing that have evaluated novel antithrombotic therapy in this setting, and these advances and their clinical practice implications will be covered during this symposium by expert faculty.
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Describe the pathophysiology and major complications of peripheral artery disease and the heightened risk in cardiometabolic patients.
- Summarize the major findings and implications of trials evaluating the role of direct oral anticoagulants in the management of high-risk patients with stable PAD
- Discuss recent data about the role of direct oral anticoagulants in patients with PAD who have undergone lower-extremity revascularization
Marc P. Bonaca MD, MPH (Chair)
Director of Vascular Research
Associate Professor of Medicine
University of Colorado School of Medicine
Dr. Bonaca discloses the following:
VOYAGER PAD was funded by a grant from Bayer to CPC Clinical Research
Grant support: Amgen, AstraZeneca, Bayer, Medtronic, Merck, Novo Nordisk, Pfizer
Deepak L. Bhatt, MD, MPH
Professor of Medicine
Harvard Medical School
Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Dr. Bhatt discloses the following:
Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda.
COMPASS was funded by Bayer.
Manesh R. Patel, MD
Chief, Division of Clinical Pharmacology
Chief, Division of Cardiology
Core Faculty in Innovation & Entrepreneurship
Member in the Duke Clinical Research Institute
Dr. Patel discloses the following:
Member of Appropriate Use Criteria Task Force: 2005-2016
Research Support: AstraZeneca, CSI, HeartFlow, Janssen, Bayer, Medtronic, National Heart, Lung, & Blood Institute
Consulting/Advisory Board: AstraZeneca, Bayer Corporation, Janssen
Off label agents: Peripheral Artery Interventions with many off label techniques and agents
Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC).
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA PRA Category 1 CreditTM
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CNE Contact Hours
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CE for Pharmacists
Postgraduate Institute for Medicine designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number (UAN): #JA4008162-9999-21-2492-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
This program offers 1.00 CPEUs for dieticians.
ABIM MOC Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 1.00 MOC
- 1.00 AMA PRA Category 1 Credit™
This course is offered through myCME.
To take this course you will be redirected to myCME's website. You must login or create an account with myCME in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!